<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0911211290
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Trioltan
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,HYDROCHLOROTHIAZIDE,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,12.5,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Macleods Pharmaceuticals Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Macleods Pharmaceuticals Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DX03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Trioltan<sup>&reg;</sup></strong> contains three active substances called olmesartan medoxomil, amlodipine (as amlodipine besylate) and hydrochlorothiazide. All three substances help to control high blood pressure.</p><p>Olmesartan medoxomil belongs to a group of medicines called &ldquo;angiotensin-II receptor antagonists&rdquo;, which lowers blood pressure by relaxing the blood vessels.</p><p>Amlodipine belongs to a group of substances called &ldquo;calcium channel blockers&rdquo;. Amlodipine also lowers blood pressure by relaxing blood vessels.</p><p>Hydrochlorothiazide is one of a group of medicines called thiazide diuretics (&ldquo;water tablets&rdquo;). It lowers blood pressure by helping the body to get rid of extra fluid by making your kidneys produce more urine.</p><p>The actions of these substances contribute to decrease your blood pressure.</p><p><strong>&nbsp;</strong></p><p><strong>Trioltan<sup>&reg;</sup> is used for the treatment of high blood pressure: </strong></p><p>In adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as fixed-dose combination, or</p><p>In patients, who are already taking a fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide plus the amlodipine as a single tablet or a fixed-dose combination of olmesartan medoxomil and amlodipine plus hydrochlorothiazide as a single tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Trioltan<sup>&reg;</sup>: </strong></p><p>If you are allergic to olmesartan medoxomil, to amlodipine or a special group of calcium channel blockers (the dihydropyridines) to hydrochlorothiazide or to substances similar to hydrochlorothiazide (sulfonamides) or to any of the other ingredients of this medicine. If you think you may be allergic talk to your doctor before taking <strong>Trioltan<sup>&reg;</sup></strong>.</p><p>If you have severe kidney problems.</p><p>If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>If you have low potassium, low sodium, high calcium or high uric acid (with symptoms of gout or kidney stones) levels in your blood that have not got better when treated.</p><p>If you are more than 3 months pregnant. (It is also better to avoid <strong>Trioltan<sup>&reg;</sup></strong> in early pregnancy).</p><p>If you have severe liver problems, if bile secretion is impaired or drainage of bile from the gall bladder is blocked (e. g. by gallstones), or if you are jaundiced (yellowing of the skin and eyes).</p><p>If you have a poor blood supply to your tissues with symptoms such as low blood pressure, low pulse, fast heartbeat or shock (including cardiogenic shock, which means shock due to severe heart troubles).</p><p>If you have very low blood pressure.</p><p>If the blood flow from your heart is slow or blocked. This may happen if the blood vessel or valve that takes blood away from your heart becomes narrow (aortic stenosis).</p><p>If you have a low heart output after a heart attack (acute myocardial infarction). Low heart output may make you feel short of breath or have swelling in your feet and ankles.</p><p>Do not take <strong>Trioltan<sup>&reg;</sup></strong> if any of the above applies to you.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>Talk to your doctor or pharmacist before using Trioltan<sup>&reg;</sup>. </strong></p><p><strong>Tell your doctor if you are taking any of the following medicines used to treat high blood pressure: </strong></p><p>An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems,</p><p>Aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p><strong>Tell your doctor if you have any of the following health problems: </strong></p><p>Kidney problems or a kidney transplant.</p><p>Liver disease.</p><p>Heart failure or problems with your heart valves or heart muscle.</p><p>Severe vomiting, diarrhea, treatment with high doses of &ldquo;water tablets&rdquo; (diuretics) or if you are on a low salt diet.</p><p>Increased levels of potassium in your blood.</p><p>Problems with your adrenal glands (hormone-producing glands on top of the kidneys).</p><p>Diabetes.</p><p>Lupus erythematosus (an autoimmune disease).</p><p>Allergies or asthma.</p><p>Skin reactions such as sunburn or rash after being in the sun or using a sunbed.<br /><strong>Contact your doctor if you experience any of the following symptoms: </strong></p><p>Diarrhea that is severe, persistent and causes substantial weight loss. Your doctor may evaluate your symptoms and decide on how to continue your blood pressure medication.</p><p>Decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking <strong>Trioltan<sup>&reg;</sup></strong>. This can lead to permanent vision impairment, if not treated.</p><p>As with any medicine, which reduces blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances of the heart or brain could lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.</p><p><strong>Trioltan<sup>&reg;</sup></strong> may cause a rise in blood fat levels and uric acid levels (the cause of gout- painful swelling of the joints). Your doctor will probably want to do a blood test from time to time to check these.</p><p>It may change the levels of certain chemicals in your blood called electrolytes. Your doctor will probably want to do a blood test from time to time to check these. Signs of electrolyte changes are: thirst, dryness of the mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, sluggish, tired, sleepy or restless, nausea, vomiting, less need to pass urine, a rapid heart rate.</p><p><strong>Tell your doctor if you notice these symptoms. </strong></p><p>If you are due to have tests for parathyroid function you should stop taking <strong>Trioltan<sup>&reg;</sup></strong> before these tests are carried out.</p><p>You must tell your doctor if you think that you are (or might become) pregnant. <strong>Trioltan<sup>&reg;</sup></strong> is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.</p><p><strong>Children and adolescents (under 18) </strong></p><p><strong>Trioltan<sup>&reg;</sup></strong> is not recommended for children and adolescents under the age of 18.</p><p><strong>Other medicines and Trioltan<sup>&reg;</sup></strong></p><p><strong>Tell your doctor or pharmacist if you are taking, have recently taken or might take any of the following: </strong></p><p>Other blood pressure lowering medicines, as the effect of <strong>Trioltan<sup>&reg;</sup></strong> can be increased. Your doctor may need to change your dose and/or to take other precautions: If you are taking an ACE-inhibitor or aliskiren.</p><p>Lithium (a medicine used to treat mood swings and some types of depression), used at the same time as <strong>Trioltan<sup>&reg;</sup></strong> may increase the toxicity of lithium. If you have to take lithium your doctor will measure your lithium blood levels.</p><p>Diltiazem, verapamil, used for heart rhythm problems and high blood pressure.</p><p>Rifampicin, erythromycin, clarithromycin, tetracyclines or sparfloxacin, antibiotics used for tuberculosis and other infections.</p><p>St. John&rsquo;s wort (Hypericum perforatum), a herbal remedy for treatment of depression.</p><p>Cisapride, used to increase food movement in the stomach and gut.</p><p>Diphemanil, used to treat a slow heartbeat or reduce sweating.</p><p>Halofantrine, used for malaria.</p><p>Vincamine IV, used to improve circulation to the nervous system.</p><p>Amantadine, used for Parkinson&rsquo;s disease.</p><p>Potassium supplements, salt substitutes containing potassium, &ldquo;water tablets&rdquo; (diuretics), heparin (for thinning the blood and prevention of blood clots), ACE inhibitors (for blood pressure lowering), laxatives, steroids, adrenocorticotrophic hormone (ACTH), carbenoxolone (a medicine used to treat mouth and stomach ulcers), penicillin G sodium (also called benzylpenicillin sodium, an antibiotic), certain pain killers such as acetylsalicylic acid (&ldquo;aspirin&rdquo;) or salicylates. Using these medicines at the same time as <strong>Trioltan<sup>&reg;</sup></strong> may alter the levels of potassium in your blood.</p><p>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis), used at The same time as <strong>Trioltan<sup>&reg;</sup></strong> may increase the risk of kidney failure. The effect of <strong>Trioltan<sup>&reg;</sup></strong>&nbsp; can be decreased by NSAIDs. In case of high dosages of salicylate the toxic effect on central nervous system may be increased.</p><p>Sleeping tablets, sedatives and anti-depressant medicines as using these medicines together with <strong>Trioltan<sup>&reg;</sup></strong> may cause a sudden drop in blood pressure when standing up.</p><p>Colesevelam hydrochloride, a drug that lowers the level of cholesterol in your blood, as the effect of <strong>Trioltan<sup>&reg;</sup></strong> may be decreased. Your doctor may advise you to take <strong>Trioltan<sup>&reg;</sup></strong> at least 4 hours before colesevelam hydrochloride.</p><p>Certain antacids (indigestion or heartburn remedies) as the effect of <strong>Trioltan<sup>&reg;</sup></strong> can be slightly decreased.</p><p>Certain muscle relaxing medicines such as baclofen and tubocurarine.</p><p>Anticholinergic agents such as atropine and biperiden.</p><p>Calcium supplements.</p><p>Dantrolene (infusion for severe body temperature abnormalities).</p><p>Simvastatin, used to lower levels of cholesterol and fats (triglycerides) in the blood.</p><p>Medicines used to control your body&rsquo;s immune response (such as tacrolimus, cyclosporine), enabling your body to accept the transplanted organ.</p><p>Also, tell your doctor or pharmacist if you are taking, have recently taken or might take any of the following medicines to:</p><p>Treat certain mental health problems such as thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, amisulpride, pimozide, sultopride, tiapride, droperidol or haloperidol.</p><p>Treat low blood sugar (e. g. diazoxide) or high blood pressure (e. g. beta-blockers, methyldopa) as <strong>Trioltan<sup>&reg;</sup></strong> can affect how these drugs work.</p><p>Treat heart rhythm problems such as mizolastine, pentamidine, terfenadine, dofetilide, ibutilide or erythromycin injections.</p><p>Treat HIV/AIDS (e. g. ritonavir, indinavir, nelfinavir).</p><p>Treat fungal infections (e. g. ketoconazole, itraconazole, amphotericin).</p><p>Treat heart problems such as quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, bepridil or digitalis.</p><p>Treat cancers such as amifostine, cyclophosphamide or methotrexate.</p><p>Increase blood pressure and slow heart rate such as noradrenaline.</p><p>Treat gout such as probenecid, sulfinpyrazone and allopurinol.</p><p>Lower blood fat levels such as colestyramine and colestipol.</p><p>Lower blood sugar such as metformin or insulin.</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>Trioltan<sup>&reg;</sup> with food and drink </strong></p><p><strong>Trioltan<sup>&reg;</sup></strong> can be taken with or without food.</p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking <strong>Trioltan<sup>&reg;</sup></strong>. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of <strong>Trioltan<sup>&reg;</sup></strong>.</p><p>Take care when drinking alcohol while you are taking <strong>Trioltan<sup>&reg;</sup></strong> as some people feel faint or dizzy. If this happens to you, do not drink any alcohol.</p><p><strong>Elderly&nbsp; </strong></p><p>If you are over 65 years of age your doctor will regularly check your blood pressure at any dose increase, to make sure that your blood pressure does not become too low.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Pregnancy </strong></p><p>You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking <strong>Trioltan<sup>&reg;</sup></strong> before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of <strong>Trioltan<sup>&reg;</sup></strong>. <strong>Trioltan<sup>&reg;</sup></strong> is not recommended during pregnancy, and must not be taken when more than 3 months pregnant as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>If you become pregnant during therapy with <strong>Trioltan<sup>&reg;</sup></strong> please inform and see your physician without delay.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding </strong></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Amlodipine and hydrochlorothiazide have been shown to pass into breast milk in small amounts. <strong>Trioltan<sup>&reg;</sup></strong> is not recommended for mothers, who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines </strong></p><p>You may feel sleepy, sick or dizzy or get a headache while being treated for your high blood pressure. If this happens do not drive or use machines until the symptoms wear off. Ask your doctor for advice.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose of <strong>Trioltan<sup>&reg;</sup></strong> is one tablet per day.</p><p>The tablet can be taken with or without food. Swallow the tablet with some fluid (such as a glass of water). The tablet should not be chewed. Do not take the tablet with grapefruit juice.</p><p>If possible, take your daily dose at the same time each day, for example at breakfast time.</p><p><strong>If you take more Trioltan<sup>&reg;&nbsp; </sup>than you should </strong></p><p>If you take more tablets than you should you may experience low blood pressure with symptoms such as dizziness, fast or slow heartbeat.</p><p>If you take more tablets than you should or if a child accidentally swallows some go to your doctor or nearest emergency department immediately and take your medicine pack or this leaflet with you.</p><p><strong>If you forget to take Trioltan<sup>&reg;</sup></strong></p><p>If you forget to take a dose take your normal dose the following day as usual. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Trioltan<sup>&reg;</sup></strong></p><p>It is important to continue to take <strong>Trioltan<sup>&reg;</sup></strong> unless your doctor tells you to stop.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If side effects do occur they are often mild and do not require treatment to be stopped.</p><p><strong>Although not many people may get them, the following two side effects can be serious: </strong></p><p>Allergic reactions with swelling of the face, mouth and/or larynx (voice box) together with itching and rash may occur during treatment with <strong>Trioltan<sup>&reg;</sup></strong>. <strong>If this happens stop taking Trioltan<sup>&reg;</sup> and contact your doctor immediately.</strong></p><p>Severe light-headedness or fainting because <strong>Trioltan<sup>&reg;</sup></strong> can cause the blood pressure to fall too low in susceptible individuals. If this happens stop taking <strong>Trioltan<sup>&reg;</sup></strong>, contact your doctor immediately and lay down flat.</p><p><strong>Trioltan<sup>&reg;</sup></strong> is a combination of three active substances. The following information firstly gives the other side effects reported so far with the combination <strong>Trioltan<sup>&reg;</sup></strong> (besides those already mentioned above) and, secondly, those side effects, which are known for each of the separate substances or when two substances are given together.</p><p>To give you an idea of how many patients might get side effects, they have been listed as common, uncommon, rare and very rare.</p><p><strong>These are the other side effects known about so far with olmesartan medoxomil/ amlodipine/hydrochlorothiazide: </strong></p><p>If these side effects occur they are often mild and you do not need to stop your treatment.</p><p><strong>Common (may affect less than 1 in 10 people) </strong></p><p>Upper respiratory tract infection; sore throat and nose; urinary tract infection; dizziness; headache; awareness of heartbeat; low blood pressure; nausea; diarrhea; constipation; cramps; joint swelling; feeling more of an urge to pass urine; weakness; ankle swelling; tiredness; abnormal laboratory values.</p><p><strong>Uncommon (may affect less than 1 in 100 people) </strong></p><p>Dizziness on standing up; vertigo; fast heartbeat; feeling faint; redness and warm feeling of the face; cough; dry mouth; muscular weakness; inability to get or maintain an erection.</p><p><strong>These are the side effects, which are known for each of the separate substances or when two substances are given together: </strong></p><p>They may be side effects for <strong>Trioltan<sup>&reg;</sup></strong>, even if they have not been seen so far with <strong>Trioltan<sup>&reg;</sup></strong>.</p><p><strong>Very common (may affect more than 1 in 10 people) </strong></p><p>Oedema (fluid retention).</p><p><strong>Common (may affect less than 1 in 10 people) </strong></p><p>Bronchitis; stomach and gut infection; vomiting; increased blood sugar; sugar in urine; confusion; feeling sleepy; visual disturbance (including double vision and blurred vision); runny or stuffy nose; sore throat; difficult breathing; cough; abdominal pain; heartburn; stomach discomfort; flatulence; pain in the joints or bones; back pain; skeletal pain; blood in the urine; flu-like symptoms; chest pain; pain.</p><p><strong>Uncommon (may affect less than 1 in 100 people) </strong></p><p>Reduced number of a type of blood cells known as platelets, which can result in bruising easily or a prolonged bleeding time; anaphylactic reactions; abnormally reduced appetite (anorexia); problems sleeping; irritability; mood changes including feeling anxious; feeling &ldquo;down&rdquo; or depressed; shiver; sleep disturbances; distorted sense of taste; loss of consciousness; reduced sense of touch; tingling sensations; worsening of shortsightedness; ringing in the ears (tinnitus); angina (pain or uncomfortable feeling in the chest, known as angina pectoris); irregular heart beat; rash; loss of hair; allergic inflammation of the skin; redness of skin; purplish spots or patches on the skin due to small haemorrhages (purpura); discolouration of the skin; red itchy bumps (hives); increased sweating; itching; eruption of the skin; skin reactions to light such as sunburn or rash; muscle pain; problems to pass urine; feeling urge to pass urine at night; breast enlargement in men; decreased sexual desire; swelling of the face; feeling unwell; weight increase or decrease; exhaustion.</p><p><strong>Rare (may affect less than 1 in 1,000 people) </strong></p><p>Swollen and sore salivary glands; reduced number of white cells in the blood, which could increase the risk of infections; low red blood cell count (anaemia); bone marrow damage; restlessness; feeling uninterested (apathy); fits (convulsions); objects you look at appearing yellow; dry eyes; blood clots (thrombosis, embolism); fluid accumulation in the lungs; pneumonia; inflammation of blood vessels and small blood vessels in the skin; inflammation of the pancreas; yellowing of the skin and eyes; acute inflammation of the gall bladder; symptoms of lupus erythematosus such as rash, joint pains and cold hands and fingers; severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome, toxic epidermal necrolysis), sometimes life-threatening; impaired movement; acute kidney failure; non-infectious kidney inflammation; poor kidney function; fever.</p><p><strong>Very Rare (may affect less than 1 in 10,000 people) </strong></p><p>High muscle tension; numbness of hands or feet; heart attack; inflammation of the stomach; thickening of the gums; blockage in the gut; inflammation of the liver.</p><p><strong>Not Known (frequency cannot be estimated from the available data) </strong></p><p>Decrease in vision or eye pain (possible signs of acute angle-closure glaucoma).</p><p>Trembling, rigid posture, mask-like face, slow movements and a shuffling, unbalanced walk.</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Trioltan<sup>&reg;</sup></strong> tablets after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Trioltan<sup>&reg;</sup></strong> tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are olmesartan medoxomil, amlodipine (as besylate) and hydrochlorothiazide.</p><p>The other ingredients are Microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry II Yellow, Opadry II Pink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Trioltan® 40/5/12.5 mg tables are Light yellow, round, biconvex, film-coated tablets debossed with ‘T22’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.
Pack size: 28 Film Coated Tablets.
Trioltan® 40/10/12.5 mg tables are Grayish red, round, biconvex, film-coated tablets debossed with ‘T24’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.
Pack size: 28 Film Coated Tablets.

To report any side effect(s):
• Saudi Arabia:
The National Pharmacovigilance Center (NPC):
SFDA Call Center: 19999 
E-mail: npc.drug@sfda.gov.sa 
Website: https://ade.sfda.gov.sa
• Other GCC States:
Please contact the relevant competent authority.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Med City Pharma-KSA.</p><p>1st Industrial city, Phase 5, Jeddah &ndash;KSA.</p><p>Tel: 00966920003288</p><p>Mobile: 00966555786968</p><p>P.O .Box: 4072 - Jeddah 22429</p><p>E-mail:&nbsp; info@medcitypharma.com</p><p><strong>Manufactured by:</strong> Macleods Pharmaceuticals Limited &ndash; India.</p><p>&nbsp;</p><p>This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2024                               
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي<strong> </strong><strong>تريولتان</strong><sup>&reg;<strong> </strong></sup>على ثلاث مواد فعالة تعرف بأولميسارتان ميدوكسوميل،أملوديبين (على شكل أملوديبين بيسايلات) وهيدروكلوروثيازيد. تساعد جميع المواد الثلاث في السيطرة على ارتفاع ضغط الدم.</p><p dir="RTL">ينتمي أولميسارتان ميدوكسوميل إلى مجموعة من الأدوية تعرف بمضادات مستقبل أنجيوتنسين-II و التي تعمل على تخفيض ضغط الدم عن طريق إرخاء الأوعية الدموية.</p><p dir="RTL">ينتمي أملوديبين إلى مجموعة من الأدوية تعرف (بحاصرات قناة الكالسيوم)، يعمل أملوديبين أيضا على تخفيض ضغط الدم عن طريق إرخاء الأوعية الدموية.</p><p dir="RTL">ينتمي هيدروكلوروثيازيد إلى مجموعة من الأدوية التي تعرف بمدرات البول الثيازيدية (أقراص الماء) ويعمل على تخفيض ضغط الدم عن طريق مساعدة الجسم في التخلص من السوائل الزائدة وذلك عن طريق تحفيز الكلى على إنتاج البول بشكل أكبر.</p><p dir="RTL">تساهم هذه المواد في تخفيض ضغط الدم.</p><p dir="RTL"><strong>يستعمل</strong><strong> </strong><strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>ارتفاع</strong><strong> </strong><strong>ضغط</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL">عند المرضى البالغين الذين يتناولون جرعة ثابتة من دواء مركب من أولميسارتان ميدوكسوميل وأملوديبين و لم يستقر لديهم ضغط الدم بشكل كافي.</p><p dir="RTL">أو عند المرضى البالغين الذين يتناولون جرعة ثابتة من دواء مركب من أولميسارتان ميدوكسوميل وهيدروكلوروثيازيد بالإضافة إلى أملوديبين كأقراص منفردة أو جرعة ثابتة من دواء مركب من أولميسارتان ميدوكسوميل وأملوديبين بالإضافة إلى هيدروكلوروثيازيد كأقراص منفردة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>.</p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>تريولتان</strong><strong><sup> &reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس لأولميسارتان ميدوكسوميل، أملوديبين، أو لمجموعة خاصة من حاصرات قناة الكالسيوم</p><p dir="RTL">(ثنائي هيدرو البيريدين)، هيدروكلوروثيازيد أو لأي مادة تشبه هيدروكلوروثيازيد (سلفوناميد)، أو لأي مكونات أخرى في هذا الدواء. إذا كنت تعتقد بأنك تعاني من تحسس، تحدث مع طبيبك&nbsp; قبل تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكلى.</p><p dir="RTL">إذا كنت تعاني من داء السكري أو قصور في وظيفة الكلى وكنت تخضع للعلاج بأحد الأدوية الخافضة لضغط الدم المحتوية على أليسكرين.</p><p dir="RTL">إذا كنت تعاني من انخفاض مستوى البوتاسيوم، الصوديوم، وارتفاع مستوى الكالسيوم أو حمض اليوريك في الدم الذي لا يتحسن عند علاجه (مع ظهور أعراض النقرس أو وجود حصوات في الكلى).</p><p dir="RTL">&nbsp;إذا كنت حامل لمدة تزيد عن 3 أشهر. (يفضل أيضا تجنب تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> خلال المراحل الأولى من الحمل).</p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكبد، إذا ضعف إفراز الصفراء أو حدوث انحصار إفراز الصفراء من المرارة (بسبب الحصاة الصفراوية)، أو إذا كنت تعاني من يرقان (اصفرار الجلد و المنطقة البيضاء في العيون).</p><p dir="RTL">إذا كنت تعاني من نقص تدفق الدم إلى الأنسجة مع ظهور أعراض مثل انخفاض ضغط الدم، ضعف النبض، تسارع نبضات القلب أو صدمة (بما في ذلك صدمة قلبية، التي تعني صدمة نتيجة لمشاكل حادة في القلب).</p><p dir="RTL">إذا كنت تعاني من انخفاض حاد في ضغط الدم.</p><p dir="RTL">إذا كان تدفق الدم من القلب بطيء أو محصور. هذا قد يحدث نتيجة لتضيق الشريان أو الصمام الذي ينقل الدم من القلب إلى جميع أنحاء الجسم (تضيق أبهري) .</p><p dir="RTL">إذا كنت تعاني من انخفاض النتاج القلبي بعد التعرض لنوبة قلبية (احتشاء حاد في عضلة القلب). قد يجعلك هذا تشعر بقصر النفس أو تورم القدمين والكاحلين.</p><p dir="RTL">لا تتناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> إذا كان أي مما ذكر في الأعلى ينطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong></p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>تريولتان</strong><strong><sup>&reg;&nbsp; </sup></strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>تستعمل</strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>ارتفاع</strong><strong> </strong><strong>ضغط</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL">أحد مثبطات الإنزيم المحول للأنجيوتنسين (مثل إنالابريل، ليزينوبريل، راميبريل)، بشكل خاص إذا كنت تعاني من مشاكل في الكلى متعلقة بداء السكري.</p><p dir="RTL">أليسكرين.</p><p dir="RTL">قد يقوم طبيبك بمراقبة وظيفة الكلى، ضغط الدم و كمية الكهرليات في الدم (مثل البوتاسيوم) خلال فترات منتظمة.</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تعاني</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المشاكل</strong><strong> </strong><strong>الصحية</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">مشاكل الكلى أو زرع الكلى.</p><p dir="RTL">مرض في الكبد.</p><p dir="RTL">قصور وظيفة عضلة القلب أو مشاكل في صمامات أو عضلة القلب.</p><p dir="RTL">تقيؤ حاد، إسهال، تناول علاج بجرعات عالية من &laquo;أقراص الماء&raquo; (مدرات البول) أو كنت تتبع نظام غذائي قليل الملح.</p><p dir="RTL">زيادة مستويات البوتاسيوم في الدم.</p><p dir="RTL">مشاكل في الغدد الكظرية (غدد مفرزة للهرمون تقع أعلى الكلى).</p><p dir="RTL">داء السكري.</p><p dir="RTL">الذأب الحمامي (مرض مناعي ذاتي).</p><p dir="RTL">الحساسية أو الربو.</p><p dir="RTL">تفاعلات جلدية مثل الإصابة بالحروق أو طفح بعد التعرض لأشعة الشمس أو استخدام الأجهزة التي تستعمل لزيادة إسمرار الجلد صناعيا.</p><p dir="RTL"><strong>تواصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">الإسهال الذي يكون حاد و مستمر و يسبب فقدان الوزن بشكل كبير. قد يقوم الطبيب بتقييم الأعراض لديك و يقرر كيفية الاستمرار بتناول أدوية علاج ضغط الدم.</p><p dir="RTL">قصور بالرؤية أو ألم في العين. قد تكون هذه أعراض ارتفاع الضغط في العين و قد يحدث خلال ساعات إلى أسابيع من تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>إذ لم يعالج قد يؤدي إلى خلل دائم في الرؤية.</p><p dir="RTL">كما هو الحال مع أي دواء خافض لضغط الدم، قد يؤدي الانخفاض الحاد في ضغط الدم عند المرضى الذين يعانون من اضطرابات في تدفق الدم إلى القلب أو الدماغ إلى حدوث نوبة قلبية أوسكتة دماغية لذلك سيراقب الطبيب ضغط الدم لديك بحذر.</p><p dir="RTL">قد يسبب <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>ارتفاع مستويات الدهون وحمض اليوريك في الدم (المسبب لمرض النقرس-تورم مؤلم في المفاصل). من المحتمل أن يطلب الطبيب القيام بفحص دم من وقت لأخر للتأكد من ذلك.</p><p dir="RTL">قد يتغير مستوى مواد كيميائية معينة في الدم تسمى الكهرليات، من المحتمل أن يطلب الطبيب القيام بفحص دم من وقت لأخر للتأكد من ذلك.</p><p dir="RTL">علامات حدوث تغير في الكهرليات هي: الشعور بالعطش، جفاف الفم، ألم في العضلات أو تشنجات، تعب في العضلات، انخفاض ضغط الدم، الشعور بالضعف، الكسل، التعب، النعاس أو عدم الراحة، غثيان، قيء، الحاجة للتبول بشكل أقل، سرعة معدل نبض القلب.</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>الأعراض</strong><strong>.</strong></p><p dir="RTL">إذا كنت ستخضع لفحص وظيفة غدد جارات الدرقية يجب التوقف عن تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>قبل القيام بهذه الفحوصات.</p><p dir="RTL">&nbsp;يجب إخبار الطبيب إذا كنت تعتقدين بأنك حامل (أو من المتوقع حصول الحمل). لا يوصى باستعمال <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> خلال المراحل الأولى من الحمل، و يجب عدم تناوله إذا كان عمر الحمل يزيد عن 3 أشهر، حيث قد يسبب أذى خطير للجنين عند استعماله خلال هذه الفترة.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المراهقون</strong><strong> (</strong><strong>الأقل</strong><strong> </strong><strong>من</strong><strong> 18 </strong><strong>عاماً</strong><strong>)</strong></p><p dir="RTL">لا يوصى باستعمال <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>للأطفال و المراهقين الذين تقل أعمارهم عن 18 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>تريولتان</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول،</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>مؤخراً</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الممكن</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">أدوية أخرى خافضة لضغط الدم، حيث قد يزيد مفعول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong>. قد يحتاج الطبيب إلى تغيير جرعتك و/ أو اتخاذ احتياطات أخرى: إذا كنت تتناول أحد مثبطات الإنزيم المحول للأنجيوتنسين أو أليسكرين.</p><p dir="RTL">ليثيوم (دواء يستعمل لعلاج تقلبات المزاج و بعض أنواع الاكتئاب)، استعماله بشكل متزامن مع <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>قد يزيد من سمية الليثيوم. إذا كان من الضروري تناول الليثيوم، سيقوم الطبيب بقياس مستويات الليثيوم لديك في الدم.</p><p dir="RTL">ديلتيازم، ڤيراباميل، تستعمل لعلاج عدم انتظام نبضات القلب وارتفاع ضغط الدم.</p><p dir="RTL">ريفامبيسين، إريثرومايسين، كلاريثرومايسين، تيتراسايكلن أو سبارفلوكساسين، مضادات حيوية تستعمل لعلاج السل و التهابات أخرى.</p><p dir="RTL">عشبة سانت جون (هايبريكم بورفوراتوم)، دواء عشبي لعلاج الاكتئاب.</p><p dir="RTL">سيسابرايد، يستعمل لزيادة حركة الطعام في المعدة والأمعاء.</p><p dir="RTL">ديفيمانيل، يستعمل لعلاج بطء نبضات القلب أو تقليل التعرق.</p><p dir="RTL">&nbsp;هالوفانترين، يستعمل لعلاج الملاريا.</p><p dir="RTL">فينكاميسين عن طريق الحقن الوريدي، يستعمل لتحسين الدورة الدموية في الجهاز العصبي.</p><p dir="RTL">&nbsp;أمانتادين، يستعمل لعلاج مرض باركنسون.</p><p dir="RTL">مكملات البوتاسيوم، بدائل الأملاح المحتوية على البوتاسيوم، &laquo; أقراص الماء&raquo; (مدرات البول)، هيبارين (للوقاية من تجلط الدم)، مثبطات الإنزيم المحول للأنجيوتنسين (لخفض ضغط الدم)، الملينات، الستيرويدات، هرمونات قشرة الغدة الكظرية، كاربينوكسولون (دواء يستعمل لعلاج تقرحات الفم والمعدة) ، بينسيلين ج صوديوم (يسمى أيضا بنزيل بينسيلين، مضاد حيوي)، مسكنات معينة للألم مثل حمض الأسيتيل ساليسيليك (الأسبرين) أو ساليسايلات. إن استعمال هذه الأدوية بشكل متزامن مع <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> قد يؤدي إلى تغير مستويات البوتاسيوم في الدم.</p><p dir="RTL">الأدوية غير الستيرويدية المضادة للالتهاب (أدوية تستعمل لتخفيف الألم، التورم وأعراض أخرى للالتهاب، بما في ذلك التهاب المفاصل الروماتزمي)، استعمالها بشكل متزامن مع <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> قد يزيد من خطر التعرض لقصور وظيفة الكلى.</p><p dir="RTL">قد ينخفض مفعول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> عند تناول الأدوية غير الستيرويدية المضادة للالتهاب بشكل متزامن. في حالة تناول جرعات عالية من الساليسالات قد يزيد التأثير السمي على الجهاز العصبي المركزي.</p><p dir="RTL">أقراص النوم، المسكنات و الأدوية المضادة للاكتئاب حيث أن استعمال هذه الأدوية بالتزامن مع <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>قد يسبب انخفاض مفاجئ في ضغط الدم عند الوقوف.</p><p dir="RTL">كوليسيڤيلام هيدروكلوريد، دواء يستعمل لخفض مستوى الكوليستيرول في الدم، حيث قد يقل مفعول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> قد ينصحك الطبيب بتناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> قبل 4 ساعات على الأقل من تناول كوليسيڤيلام هيدروكلوريد.</p><p dir="RTL">بعض مضادات الحموضة (أدوية عسر الهضم أو حرقة المعدة)، حيث قد يقل مفعول <strong>تريولتان</strong><strong><sup>&reg; </sup></strong>بشكل بسيط.</p><p dir="RTL">&nbsp; بعض الأدوية المرخية للعضلات مثل باكلوفين و تيوبوكيوراربن.</p><p dir="RTL">&nbsp;العوامل المضادة للكولين مثل أتروبين و بايبيريدين.</p><p dir="RTL">&nbsp;مكملات الكالسيوم.</p><p dir="RTL">&nbsp;دانترولين (حقن بطيء لعلاج الاضطرابات الحادة في درجة حرارة الجسم).</p><p dir="RTL">سيمڤاستاتين، يستعمل لتخفيض مستويات الكوليستيرول والدهون ( الجليسيريدات الثلاثية) في الدم.</p><p dir="RTL">الأدوية التي تستعمل للسيطرة على رد الفعل المناعي في الجسم مثل (تاكروليمس، سيكلوسبورين)، و التي تسمح للجسم بتقبل العضو المزروع.</p><p dir="RTL">أيضا أخبر الطبيب أو الصيدلاني إذا كنت تتناول أو تناولت مؤخراً أومن الممكن أن تتناول أي من الأدوية التالية:</p><p dir="RTL">لعلاج بعض مشاكل الصحة العقلية مثل ثيورايدازين، كلوربرومازين، ليڤوميبرومازين، ترايفلوبيرازين، سياميمازين، سلبرايد، أميسلبرايد، بيموزايد، سلتوبرايد، تيابرايد، دروبيرايدول أو هالوبيرايدول.</p><p dir="RTL">لعلاج انخفاض مستوى السكر في الدم (مثل ديازوكسايد) أو ارتفاع ضغط الدم (مثل حاصرات بيتا، ميثيل دوبا) حيث قد يؤثر <strong>تريولتان</strong><strong><sup>&reg; </sup></strong>على طريقة عمل هذه الأدوية.</p><p dir="RTL">لعلاج عدم انتظام نبضات القلب مثل ميزولاستين، بينتاميدين، تيرفينادين، دوفيتيلايد، إيبوتيلايد أو إيريثرومايسين عن طريق الحقن.</p><p dir="RTL">لعلاج ڤيروس نقص المناعة المكتسبة / الإيدز (مثل ريتوناڤير، إنديناڤير، نلفيناڤير).</p><p dir="RTL">&nbsp;لعلاج الالتهابات الناتجة عن الفطريات (مثل كيتوكونازول، إتراكونازول، أمفوتيريسين).</p><p dir="RTL">لعلاج مشاكل القلب مثل كوينيدين، هيدروكوينيدين، ديسوبيراميد، أميودارون، سوتالول، بيبريديل أو ديجيتاليس.</p><p dir="RTL">لعلاج السرطانات مثل أميفوستين، سايكلوفوسفاميد أو ميثوتريكسيت.</p><p dir="RTL">لعلاج ارتفاع ضغط الدم و بطء معدل نبضات القلب مثل نورأدرينالين.</p><p dir="RTL">لعلاج النقرس مثل بروبنسيد، سلفينييرازون و الوبيورينول.</p><p dir="RTL">لعلاج انخفاض مستويات الدهون في الدم مثل كوليستيرامين و كوليستيبول.</p><p dir="RTL">لعلاج انخفاض مستوى السكر في الدم مثل ميتفورمين أو الإنسولين.</p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول ، تناولت مؤخرا أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الشراب</strong><strong> </strong></p><p dir="RTL">من الممكن تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>مع أو بدون تناول الطعام.</p><p dir="RTL">يجب عدم تناول عصير أو فاكهة الجريب فروت من قبل الأشخاص الذين يتناولون <strong>تريولتان</strong><strong><sup>&reg;</sup></strong>. وهذا لأن فاكهة الجريب فروت و عصيرها قد تؤدي إلى زيادة في مستوى المادة الفعالة أملوديبين، الذي قد يسبب زيادة غير متوقعة في تأثير <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>الخافض لضغط الدم.</p><p dir="RTL">يجب توخي الحذر عند شرب الكحول خلال فترة تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>حيث قد يشعر بعض الأشخاص بالإغماء أو الدوار. إذا حصل هذا، تجنب شرب الكحول.</p><p dir="RTL"><strong>المرضى</strong><strong> </strong><strong>كبار</strong><strong> </strong><strong>السن</strong></p><p dir="RTL">إذا كان عمرك يزيد عن 65 عام، سيقوم الطبيب بمراقبة ضغط الدم لديك بشكل منتظم عند أي زيادة في الجرعة، للتأكد من عدم حصول انخفاض حاد في ضغط الدم.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب إخبار الطبيب إذا كنت تعتقدين بأنك حامل (أو من المتوقع حصول حمل). سينصحك الطبيب عادة بالتوقف عن تناول <strong>تريولتان</strong><strong><sup>&reg; </sup></strong><strong>&nbsp;</strong>قبل حصول الحمل أو حال المعرفة بحصوله و سينصحك بتناول دواء آخر بدلاً من <strong>تريولتان</strong><strong><sup>&reg;</sup></strong>. لا يوصى بتناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>خلال فترة الحمل، ويجب عدم تناوله إذا كان عمر الحمل يزيد عن 3 أشهر، حيث قد يسبب أذى خطير للجنين عند استعماله بعد الشهر الثالث من الحمل. إذا حصل الحمل خلال فترة العلاج <strong>بتريولتان</strong><strong><sup>&reg;</sup></strong>، الرجاء إخبار الطبيب و زيارته فوراً بدون تأخير.</p><p dir="RTL"><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">أخبر الطبيب إذا كنت مرضعة أو على وشك البدء في الإرضاع. تم ملاحظة أن أملوديبين و هيدروكلوروثيازيد يفرز في حليب الثدي بكميات قليلة، لا يوصى باستعمال <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>للأمهات المرضعات و قد يختار الطبيب علاج آخر لك إذا كنت ترغبين في الإرضاع.</p><p dir="RTL">إذا كنت حامل أو مرضعة، تعتقدين بأنك حامل أو تخططين لذلك، استشيري الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>قيادة</strong><strong> </strong><strong>المركبات</strong><strong> </strong><strong>و</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد تشعر بالنعاس، المرض أو الدوار أو يحصل لديك صداع أثناء فترة علاج ارتفاع ضغط الدم. إذا حصل هذا، تجنب قيادة المركبات أو استخدام الآلات إلى أن تختفي الأعراض لديك، استشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائما كما أخبرك طبيبك أو الصيدلي. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">الجرعة الموصى بها من <strong>تريولتان</strong><strong><sup>&reg; </sup></strong>هي قرص واحد يومياً.</p><p dir="RTL">من الممكن تناول الأقراص مع أو بدون تناول الطعام. تناول القرص مع شرب كمية من السائل (مثل كوب واحد من الماء). يجب عدم مضغ الأقراص. لا تتناولها مع عصير جريب فروت.</p><p dir="RTL">إذا أمكن، تناول الجرعة اليومية في نفس الوقت يومياً، مثلا وقت تناول وجبة الإفطار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>قمت</strong><strong> </strong><strong>بتناول</strong><strong> </strong><strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذا تناولت أقراص أكثر مما يجب قد يحصل لديك انخفاض في ضغط الدم مع ظهور أعراض مثل الشعور بالدوار، تسارع أو تباطؤ نبضات القلب.</p><p dir="RTL">إذا تناولت أقراص أكثر مما يجب أو تناول طفلك بعض من الأقراص عن طريق الخطأ، اذهب إلى الطبيب أو أقرب قسم طوارىء فوراً و أصطحب عبوة الدواء أو هذه النشرة معك.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>تريولتان</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">إذا نسيت تناول الجرعة، تناول الجرعة المعتادة في اليوم التالي كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>تريولتان</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">من الضروري الاستمرار بتناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>ما لم يخبرك الطبيب بالتوقف عن ذلك</p><p dir="RTL">&nbsp;إذا كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، أسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع. إذا حدثت، فإنها عادة تكون معتدلة و لا تستدعي التوقف عن تناول العلاج.</p><p dir="RTL"><strong>على</strong><strong> </strong><strong>الرغم</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أنها</strong><strong> </strong><strong>لا</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>العديد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأشخاص،</strong><strong> </strong><strong>إلا</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>الأثرين</strong><strong> </strong><strong>الجانبيين</strong><strong> </strong><strong>التاليين</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>خطيرة</strong><strong>:</strong></p><p dir="RTL">تفاعلات تحسسية خلال فترة العلاج ب <strong>تريولتان</strong><strong><sup>&reg;</sup></strong> مع تورم الوجه، الفم، و/ أو الحنجرة يرافقه حكة و طفح، <strong>في</strong><strong> </strong><strong>حال</strong><strong> </strong><strong>حدوث</strong><strong> </strong><strong>ذلك</strong> <strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong> <strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>و <strong>اتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فورا</strong>.</p><p dir="RTL">الشعور بالدوار الحاد أو الإغماء لأن <strong>تريولتان</strong><strong><sup>&reg; </sup></strong>قد يسبب انخفاض حاد في ضغط الدم عند الأشخاص المتوقع حدوث ذلك لديهم. إذا حصل هذا توقف عن تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong>، اتصل مع طبيبك فوراً واستلقي.</p><p dir="RTL">إن <strong>تريولتان</strong><strong><sup>&reg; </sup></strong>مركب من ثلاث مواد فعالة. إن المعلومات التالية أولا تشمل الآثار الجانبية الأخرى التي تم تسجيلها حتى الآن عند تناول <strong>تريولتان</strong><strong><sup>&reg; </sup></strong>كدواء مركب من ثلاث مواد فعالة (إلى جانب الأدوية التي ذكرت في الأعلى) و ثانيا الآثار الجانبية المعروفة لكل مادة لوحدها أو عند إعطاء مادتين معا.</p><p dir="RTL">لإعطاءك فكرة عن عدد المرضى الذين من الممكن أن تحصل لديهم آثار جانبية، تم تصنيفهم كآثار جانبية شائعة، غير شائعة، نادرة و نادرة جدا.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>معروفة</strong><strong> </strong><strong>حتى</strong><strong> </strong><strong>الآن</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>أولميسارتان</strong><strong> </strong><strong>ميدوكسوميل</strong><strong> /</strong><strong>أملوديبين</strong><strong>/ </strong><strong>هيدروكلوروثيازيد</strong><strong>.</strong></p><p dir="RTL">إذا حدثت هذه الآثار الجانبية فإنها عادة تكون معتدلة ولا تستدعي التوقف عن تناول العلاج.</p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">التهاب الجهاز التنفسي العلوي، التهاب الحلق والأنف، التهاب الجهاز البولي، الشعور بالدوار، صداع، الإحساس بنبض القلب، انخفاض ضغط الدم، الشعور بالغثيان، الإسهال، الإمساك، تشنجات عضلية، تورم المفاصل، الشعور بالحاجة أكثر للتبول، الشعور بالضعف، تورم الكاحلين، الشعور بالتعب، قيم غير طبيعية للفحوصات المخبرية.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">الشعور بالدوار عند الوقوف، رنح، سرعة نبضات القلب، الشعور بالإغماء، احمرار الوجه وشعور بدفئه، سعال، جفاف الفم، ضعف العضلات، عدم القدرة على حصول الانتصاب أو المحافظة عليه.</p><p dir="RTL"><strong>الأثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>المعروفة</strong><strong> </strong><strong>لكل</strong><strong> </strong><strong>مادة</strong><strong> </strong><strong>فعالة</strong><strong> </strong><strong>لوحدها</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>إعطاء</strong><strong> </strong><strong>مادتين</strong><strong> </strong><strong>معا</strong><strong>:</strong></p><p dir="RTL">قد تحصل هذه الأثار الجانبية عند تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong>، حتى وإن لم يتم ملاحظتها حتى الآن عند تناول <strong>تريولتان</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>شائعة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">وذمة (احتباس سوائل).</p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">التهاب القصبات، التهاب المعدة والأمعاء، قيء، ارتفاع مستوى السكر في الدم، ظهور السكر في البول، ارتباك، الشعور بالنعاس، اضطراب في الرؤية (و يشمل ازدواجية الرؤية و الرؤية الضبابية)،&nbsp; سيلان أو احتقان الأنف، التهاب الحلق، صعوبة في التنفس، سعال، ألم في البطن، حرقة، الشعور بعدم الراحة في منطقة المعدة، نفخة في البطن، ألم في المفاصل أو العظام، ألم في الظهر، ألم هيكلي، ظهور الدم في البول، أعراض تشبه الإنفلونزا، ألم في الصدر، ألم.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">انخفاض في عدد نوع من خلايا الدم تعرف بالصفيحات، الذي قد يؤدي إلى التعرض للكدمات بسهولة أو للنزيف لوقت طويل، تفاعلات فرط الحساسية، فقدان الشهية بشكل غير طبيعي، مشاكل في النوم، سرعة الغضب، تغيرات المزاج بما في ذلك شعور بالقلق، الشعور بالإحباط أو الإكتئاب، قشعريرة، اضطرابات النوم، اضطراب في حاسة التذوق، فقدان الوعي، قلة الإحساس باللمس، الإحساس بوخز خفيف، ازدياد قصر النظر سوءا، رنين في الأذنين (طنين)، ذبحة صدرية (ألم أو شعور بعدم الراحة في الصدر يعرف بالذبحة الصدرية)، عدم انتظام نبضات القلب، طفح، تساقط الشعر، التهاب تحسسي في الجلد، احمرار الجلد، بقع أرجوانية اللون أو لطخات على الجلد نتيجة الإصابة بنزيف بسيط (فرفرية)، تلون الجلد، نتوءات حمراء تسبب الحكة (شرى)، زيادة التعرق، حكة، طفح جلدي، تفاعلات جلدية للضوء مثل حروق نتيجة التعرض لأشعة الشمس أو طفح، ألم في العضلات، مشاكل في التبول، شعور ملح للتبول خلال الليل، تضخم الثدي عند الرجال، انخفاض الرغبة الجنسية، تورم الوجه، الشعور بالمرض، زيادة أو نقصان الوزن، إنهاك.</p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">تورم و التهاب الغدد اللعابية، انخفاض في عدد الخلايا البيضاء في الدم، الذي قد يزيد من خطورة التعرض للالتهابات، انخفاض في تعداد خلايا الدم الحمراء (فقر الدم)، تلف نخاع العظم، شعور بعدم الراحة، لا مبالاة، نوبات ظهور أعراض مفاجنة (تشنجات)، رؤية الأشياء باللون الأصفر، جفاف العيون، تجلطات دموية (تجلط، انسداد وعائي)، تجمع السوائل في الرئتين، التهاب رئوي، التهاب الأوعية الدموية والأوعية الدموية الصغيرة في الجلد، التهاب البنكرياس، اصفرار الجلد والمنطقة البيضاء في العيون، التهاب حاد في المرارة، أعراض الذأب الحمامي مثل طفح، ألم في المفاصل، وبرودة اليدين والأصابع، تفاعلات جلدية حادة و يشمل طفح جلدي، شرى، احمرار الجلد في كافة أنحاء الجسم، حكة حادة، تنفط، تقشر و تورم في الجلد، التهاب في الأغشية المخاطية (متلازمة ستفين جونسون، انحلال نخري سام في البشرة)، في بعض الأحيان قد يكون مهدد للحياة ضعف الحركة، قصور حاد في وظيفة الكلى، التهاب غير معدي في الكلى، ضعف وظيفة الكلى، حمى.</p><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جداً</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">زيادة في تشنج العضلات، تنمل في اليدين أو القدمين، نوبة قلبية، التهاب في المعدة، سماكة اللثة، انسداد في الأمعاء، التهاب الكبد.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>)</strong></p><p dir="RTL">ضعف في الرؤية أو ألم في العينين(علامات محتملة لحدوث جلوكوما الزاوية الحادة المغلقة).</p><p dir="RTL">ارتعاش، وضعية جسم متصلبة، وجه يشبه القناع، حركات بطيئة وعن طريق جر القدم، مشي غير منتظم.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong>&nbsp; </strong><strong>تحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي،</strong><strong> </strong><strong>و</strong><strong> </strong><strong>يشمل</strong><strong> </strong><strong>ذلك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل<strong> </strong>أقراص <strong>تريولتان</strong><strong><sup>&reg; </sup></strong>بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط و العبوة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> </strong>أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي أولميسارتان ميدوكسوميل، أملوديبين(أملوديبين بيسايلات)، هيدروكلوروثيازيد.<strong> </strong></p><p dir="RTL">المكونات الأخرى هي ميكروكريستالين سليلوز، نشا، كروسكارميلوز صوديوم، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم، أوبادري II أصفر، أوبادري II وردي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> 12.5/5/40 </strong><strong>ملغم</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>مغلفة</strong><strong> </strong></p><p dir="RTL">أقراص مغلفة دائرية الشكل ذات لون أصفر فاتح، محدبة الوجهين، و محفور على أحد الأوجه T22، معبأة في أشرطة Alu/Alu، معدة للاستخدام عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong></p><p dir="RTL">28 قرص مغلف</p><p dir="RTL"><strong>تريولتان</strong><strong><sup>&reg;</sup></strong><strong> 12.5/10/40 </strong><strong>ملغم</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>مغلفة</strong></p><p dir="RTL">أقراص مغلفة دائرية الشكل ذات لون أحمر مائل إلى الرمادي، محدبة الوجهين، و محفور على أحد الأوجه T24، معبأة في أشرطة Alu/Alu، معدة للاستخدام عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong></p><p dir="RTL">28 قرص مغلف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لللإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&bull; </strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull; </strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>العربي</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">المدينة الصناعية الأولى، المرحلة الخامسة، جدة- المملكة العربية السعودية.</p><p dir="RTL">الهاتف: 00966920003288&nbsp;</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 4072 &ndash; جدة 22429</p><p dir="RTL">البريد الإلكتروني: info@medcitypharma.com</p><p dir="RTL"><strong>تصنيع</strong>: شركة ماكلويد الدوائية المحدودة - الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2024                               
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trioltan® 40/5/12.5 mg Film Coated Tablets.
Trioltan® 40/10/12.5 mg Film Coated Tablets.
Olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg Film Coated Tablets.
Olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trioltan® 40/5/12.5 mg: Each film-coated tablet contains 40 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besylate) and 12.5 mg hydrochlorothiazide. 
Trioltan® 40/10/12.5 mg: Each film-coated tablet contains 40 mg of olmesartan medoxomil, 10 mg of amlodipine (as amlodipine besylate) and 12.5 mg hydrochlorothiazide.

For a full list of excipients: see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
Trioltan® 40/5/12.5 mg tables are Light yellow, round, biconvex, film-coated tablets debossed with ‘T22’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.
Trioltan® 40/10/12.5 mg tables are Grayish red, round, biconvex, film-coated tablets debossed with ‘T24’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.</p><p><strong><em>Add-on therapy</em></strong></p><p><strong>Trioltan<sup>&reg; </sup></strong>is indicated in adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.</p><p><strong><em>Substitution therapy</em></strong></p><p><strong>Trioltan<sup>&reg;</sup></strong> is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (olmesartan medoxomil and amlodipine or olmesartan medoxomil and hydrochlorothiazide) and a single-component formulation (hydrochlorothiazide or amlodipine).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong>Adults</strong></p><p>The recommended dose of <strong>Trioltan<sup>&reg;</sup></strong> is 1 tablet per day.</p><p><strong><em>Add-on therapy</em></strong></p><p>Olmesartan medoxomil/amlodipine/hydrochlorothiazide<strong><sup> </sup></strong>20/5/12.5 mg may be administered in patients whose blood pressure is not adequately controlled on olmesartan medoxomil 20 mg and amlodipine 5 mg taken as dual-component combination.</p><p><strong>Trioltan<sup>&reg; </sup></strong>40/5/12.5 mg may be administered in patients whose blood pressure is not adequately controlled on olmesartan medoxomil 40 mg and amlodipine 5 mg taken as dual-component combination or in patients whose blood pressure is not adequately controlled on olmesartan medoxomil/amlodipine/hydrochlorothiazide<strong><sup> </sup></strong>20/5/12.5 mg.</p><p>Olmesartan medoxomil/amlodipine/hydrochlorothiazide<strong><sup> </sup></strong>40/5/25 mg may be administered in patients whose blood pressure is not adequately controlled on <strong>Trioltan<sup>&reg; </sup></strong>40/5/12.5 mg.</p><p><strong>Trioltan<sup>&reg;</sup></strong> 40/10/12.5 mg may be administered in patients whose blood pressure is not adequately controlled on olmesartan medoxomil 40 mg and amlodipine 10 mg taken as dual-component combination or by <strong>Trioltan<sup>&reg;</sup></strong> 40/5/12.5 mg.</p><p>olmesartan medoxomil/amlodipine/hydrochlorothiazide<strong><sup> </sup></strong>40/10/25 mg may be administered in patients whose blood pressure is not adequately controlled on <strong>Trioltan<sup>&reg;</sup></strong> 40/10/12.5 mg or by olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg.</p><p>A step-wise titration of the dosage of the individual components is recommended before changing to the triple-component combination. When clinically appropriate, direct change from dual-component combination to the triple-component combination may be considered.</p><p><strong><em>Substitution therapy</em></strong></p><p>Patients controlled on stable doses of olmesartan medoxomil, amlodipine and hydrochlorothiazide taken at the same time as a dual-component (olmesartan medoxomil and amlodipine or olmesartan medoxomil and hydrochlorothiazide) and a single-component formulation (hydrochlorothiazide or amlodipine) may be switched to <strong>Trioltan<sup>&reg;</sup></strong> containing the same component doses.</p><p>The maximum recommended dose of olmesartan medoxomil/amlodipine/hydrochlorothiazide<strong><sup> </sup></strong>is 40/10/25 mg per day.</p><p><strong>Elderly (age 65 years or over)</strong></p><p>Caution, including more frequent monitoring of blood pressure, is recommended in elderly people, particularly at the maximum dose of olmesartan medoxomil/amlodipine/hydrochlorothiazide<strong><sup> </sup></strong>40/10/25 mg per day.</p><p>An increase of the dosage should take place with care in elderly people (see sections 4.4 and 5.2).</p><p>Very limited data are available on the use of olmesartan medoxomil/amlodipine/hydrochlorothiazide in patients aged 75 years or older. Extreme caution, including more frequent monitoring of blood pressure, is recommended.</p><p><strong>Renal impairment</strong></p><p>The maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 30-60 mL/min) is olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg, owing to limited experience of the 40 mg olmesartan medoxomil dosage in this patient group.</p><p>Monitoring of serum concentrations of potassium and creatinine is advised in patients with moderate renal impairment.</p><p>The use of <strong>Trioltan<sup>&reg; </sup></strong>in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) is contraindicated (see sections 4.3, 4.4 and 5.2).</p><p><strong>Hepatic impairment</strong></p><p><strong>Trioltan<sup>&reg;</sup></strong> should be used with caution in patients with mild hepatic impairment (see sections 4.4 and 5.2).</p><p>In patients with moderate hepatic impairment the maximum dose should not exceed olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg once daily. Close monitoring of blood pressure and renal function is advised in patients with hepatic impairment.</p><p>As with all calcium antagonists, amlodipine&#39;s half-life is prolonged in patients with impaired liver function and dosage recommendations have not been established. <strong>Trioltan<sup>&reg; </sup></strong>should therefore be administered with caution in these patients. The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with impaired liver function.</p><p>Use of <strong>Trioltan<sup>&reg; </sup></strong>is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 5.2), cholestasis or biliary obstruction (see section 4.3).</p><p><strong>Paediatric population</strong></p><p><strong>Trioltan<sup>&reg; </sup></strong>is not recommended for use in patients aged below 18 years due to a lack of data on safety and efficacy.</p><p><strong><u>Method of administration:</u></strong></p><p>The tablet should be swallowed with a sufficient amount of fluid (e. g. one glass of water). The tablet should not be chewed and should be taken at the same time each day.</p><p><strong>Trioltan<sup>&reg; </sup></strong>can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to dihydropyridine derivates or to sulfonamide-derived substances (since hydrochlorothiazide is a sulfonamide-derived drug) or to any of the excipients listed in section 6.1.
Severe renal impairment (see sections 4.4 and 5.2).
Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.
Severe hepatic insufficiency, cholestasis and biliary obstructive disorders (see section 5.2).
2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6).
The concomitant use of Trioltan® with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1). 
Due to the amlodipine component, Trioltan® is contraindicated in patients with:
- Shock (including cardiogenic shock).
- Severe hypotension.
- Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis).
- Haemodynamically unstable heart failure after acute myocardial infarction.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Patients with hypovolaemia or sodium depletion:</strong></p><p>Symptomatic hypotension may occur in patients who are volume and/or sodium depleted as a result of vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting, especially after the first dose. Correction of this condition prior to administration of <strong>Trioltan<sup>&reg;</sup></strong> or close medical supervision at the start of the treatment is recommended.</p><p><strong>Other conditions with stimulation of the renin-angiotensin-aldosterone system:</strong></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e. g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure.</p><p><strong>Renovascular hypertension:</strong></p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.</p><p><strong>Renal impairment and kidney transplantation:</strong></p><p>When <strong>Trioltan<sup>&reg; </sup></strong>is used in patients with impaired renal function, periodic monitoring of serum concentrations of potassium and creatinine is recommended.</p><p>Use of <strong>Trioltan<sup>&reg; </sup></strong>is not recommended in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) (see sections 4.2, 4.3 and 5.2).</p><p>Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function.</p><p>If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration given to discontinuing diuretic therapy.</p><p>There is no experience of the administration of <strong>Trioltan<sup>&reg; </sup></strong>in patients with a recent kidney transplant or in patients with end-stage renal impairment (i. e. creatinine clearance &lt; 12 mL/min).</p><p><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</strong></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><strong>Hepatic impairment:</strong></p><p>Exposure to amlodipine and olmesartan medoxomil is increased in patients with hepatic impairment (see section 5.2).</p><p>Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.</p><p>Care should be taken when <strong>Trioltan<sup>&reg; </sup></strong>is administered in patients with mild to moderate hepatic impairment.</p><p>In patients with moderate hepatic impairment, the dose of olmesartan medoxomil should not exceed 20 mg (see section 4.2).</p><p>In patients with impaired hepatic function, amlodipine should be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose.</p><p>Use of <strong>Trioltan<sup>&reg; </sup></strong>is contraindicated in patients with severe hepatic impairment, cholestasis or biliary obstruction (see section 4.3).</p><p><strong>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:</strong></p><p>Due to the amlodipine component of <strong>Trioltan<sup>&reg;</sup></strong>, as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><strong>Primary aldosteronism:</strong></p><p>Patients with primary aldosteronism generally will not respond to anti-hypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of <strong>Trioltan<sup>&reg; </sup></strong>is not recommended in such patients.</p><p><strong>Metabolic and endocrine effects:</strong></p><p>Thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required (see section 4.5). Latent diabetes mellitus may become manifest during thiazide therapy.</p><p>Increases in cholesterol and triglyceride levels are undesirable effects known to be associated with thiazide diuretic therapy.</p><p>Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide therapy.</p><p><strong>Electrolyte imbalance:</strong></p><p>As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscle fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting (see section 4.8).</p><p>The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH (see section 4.5).</p><p>Conversely, due to antagonism at the angiotensin-II receptors (AT<sub>1</sub>) through the olmesartan medoxomil component of <strong>Trioltan<sup>&reg;</sup></strong> hyperkalaemia may occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Close monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes and other medicinal products that may increase serum potassium levels (e. g. heparin) should be co-administered cautiously with <strong>Trioltan<sup>&reg;</sup></strong> (see section 4.5) and with frequent monitoring of potassium levels.</p><p>There is no evidence that olmesartan medoxomil would reduce or prevent diuretic-induced hyponatraemia. Chloride deficit is generally mild and usually does not require treatment.</p><p>Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.</p><p>Hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.</p><p>Dilutional hyponatraemia may occur in oedematous patients in hot weather.</p><p><strong>Lithium:</strong></p><p>As with other angiotensin II receptor antagonists, the coadministration of <strong>Trioltan<sup>&reg; </sup></strong>and lithium is not recommended (see section 4.5).</p><p><strong>Heart failure:</strong></p><p>As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals.</p><p>In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death.</p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study of amlodipine in patients with severe heart failure (NYHA III and IV), the reported incidence of pulmonary oedema was higher in the amlodipine group than in the placebo group (see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p><strong>Sprue-like enteropathy:</strong></p><p>In very rare cases severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan few months to years after drug initiation, possibly caused by a localized delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence of other apparent etiologies, olmesartan treatment should be immediately discontinued and should not be restarted. If diarrhea does not improve during the week after the discontinuation, further specialist (e.g. a gastro-enterologist) advice should be considered.</p><p><strong>Acute Myopia and Secondary Angle-Closure Glaucoma</strong></p><p>Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy (see section 4.8).</p><p><strong>Pregnancy:</strong></p><p>Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><strong>Paediatric population:</strong></p><p><strong>Trioltan<sup>&reg; </sup></strong>is not indicated in children and adolescents under the age of 18 years.</p><p><strong>Elderly:</strong></p><p>In the elderly, increase of the dosage should take place with care (see section 5.2).</p><p><strong>Photosensitivity:</strong></p><p>Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment with <strong>Trioltan<sup>&reg;</sup></strong>, it is recommended to stop the treatment. If re-administration of the diuretic is deemed necessary, it is recommended to protect the areas exposed to the sun or to artificial UVA.</p><p><strong>Other:</strong></p><p>As with any antihypertensive agent, excessive blood pressure reduction in patients with ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p>Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.</p><p>Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.</p><p>As with all other angiotensin II receptor antagonists, the blood pressure lowering effect of olmesartan is somewhat less in black patients than in non-black patients, however, this effect was not seen in one of the three clinical trials with olmesartan medoxomil/amlodipine/hydrochlorothiazide that included black patients (30 %), see also section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Potential interactions related to the </strong><strong>Trioltan<sup>&reg; </sup></strong><strong>combination:</strong></p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>Lithium:</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely, with angiotensin II receptor antagonists. In addition, renal clearance of lithium is reduced by thiazides and consequently the risk of lithium toxicity may be increased. Therefore use of <strong>Trioltan<sup>&reg; </sup></strong>and lithium in combination is not recommended (see section 4.4). If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><strong><em>Concomitant use requiring caution</em></strong></p><p><em>Baclofen:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Non-steroidal anti-inflammatory medicinal products:</em></p><p>NSAIDs (i.e. acetylsalicylic acid (&gt; 3 g/day), COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of thiazide diuretics and angiotensin II receptor antagonists.</p><p>In some patients with compromised renal function (e. g. dehydrated patients or elderly people with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.</p><p><strong><em>Concomitant use to be taken into account</em></strong></p><p><em>Amifostine:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Other antihypertensive agents:</em></p><p>The blood pressure lowering effect of <strong>Trioltan<sup>&reg; </sup></strong>can be increased by concomitant use of other antihypertensive medicinal products.</p><p><em>Alcohol, barbiturates, narcotics or antidepressants:</em></p><p>Potentiation of orthostatic hypotension may occur.</p><p><strong>Potential interactions related to olmesartan medoxomil:</strong></p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>ACE-inhibitors, angiotensin II receptor blockers or aliskiren:</em></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><em>Medicinal products affecting potassium levels:</em></p><p>Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal products that affect potassium are to be prescribed in combination with <strong>Trioltan<sup>&reg;</sup></strong>, monitoring of serum potassium is advised.</p><p><strong><em>Additional information</em></strong></p><p><em>Bile acid sequestering agent colesevelam:</em></p><p>Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan and reduces t1/2. Administration of olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before the colesevelam hydrochloride dose should be considered (see section 5.2).</p><p>After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed.</p><p>Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.</p><p>Coadministration of olmesartan medoxomil with pravastatin had no clinically relevant effects on the pharmacokinetics of either component in healthy subjects.</p><p>Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4&nbsp;<em>in vitro</em>, and had no or minimal inducing effects on rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and medicinal products metabolised by the above cytochrome P450 enzymes are expected.</p><p><strong>Potential interactions related to amlodipine</strong></p><p><strong><em>Concomitant use requiring caution</em></strong></p><p><em>Effects of other medicinal products on amlodipine</em></p><p>CYP3A4 inhibitors:</p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>CYP3A4 inducers:</p><p>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (i. e. rifampicin, hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p>Dantrolene (infusion): In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p><em>Effects of amlodipine on other medicinal products</em></p><p>The blood pressure-lowering effect of amlodipine adds to the blood pressure-lowering effects of other antihypertensive agents.</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin or warfarin.</p><p>Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p><p>Tacrolimus: There is a risk of increased tacrolimus blood levels when co-administered with amlodipine but the pharmacokinetic mechanism of this interaction is not fully understood. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p><p>Cyclosporine: In a prospective study in renal transplant patients, an average 40% increase in trough cyclosporine levels was observed when used concomitantly with amlodipine. The co-administration of <strong>Trioltan<sup>&reg; </sup></strong>with cyclosporine may increase exposure to cyclosporine. Monitor trough cyclosporine levels during concomitant use and cyclosporine dose reductions should be made as necessary.</p><p><strong>Potential interactions related to hydrochlorothiazide</strong>:</p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>Medicinal products affecting potassium levels:</em></p><p>The potassium-depleting effect of hydrochlorothiazide (see section 4.4) may be potentiated by the coadministration of other medicinal products associated with potassium loss and hypokalaemia (e. g. other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium or salicylic acid derivatives). Such concomitant use is therefore not recommended.</p><p><strong><em>Concomitant use requiring caution</em></strong></p><p><em>Calcium salts:</em></p><p>Thiazide diuretics may increase serum calcium owing to decreased excretion. If calcium supplements must be prescribed, serum calcium should be monitored and calcium dosage adjusted accordingly.</p><p><em>Cholestyramine and colestipol resins:</em></p><p>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.</p><p><em>Digitalis glycosides:</em></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias.</p><p><em>Medicinal products affected by serum potassium disturbances:</em></p><p>Periodic monitoring of serum potassium and ECG is recommended when <strong>Trioltan<sup>&reg; </sup></strong>is administered with medicinal products affected by serum potassium disturbances (e. g. digitalis glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes (ventricular tachycardia):</p><p>- Class Ia antiarrhythmics (e. g. quinidine, hydroquinidine, disopyramide).</p><p>- Class III antiarrhythmics (e. g. amiodarone, sotalol, dofetilide, ibutilide).</p><p>- Some antipsychotics (e. g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).</p><p>- Others (e. g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacin, terfenadine, vincamine IV).</p><p><em>Non-depolarizing skeletal muscle relaxants (e. g. tubocurarine):</em></p><p>The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.</p><p><em>Anticholinergic agents (e. g. atropine, biperiden):</em></p><p>Increase of the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p><em>Antidiabetic medicinal products (oral agents and insulin):</em></p><p>The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4).</p><p><em>Metformin:</em></p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><em>Beta-blockers and diazoxide:</em></p><p>The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p><em>Pressor amines (e. g. noradrenaline):</em></p><p>The effect of pressor amines may be decreased.</p><p><em>Medicinal products used in the treatment of gout (e. g. probenecid, sulfinpyrazone and allopurinol)</em>:</p><p>Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><em>Amantadine:</em></p><p>Thiazides may increase the risk of adverse effects caused by amantadine.</p><p><em>Cytotoxic agents (e. g. cyclophosphamide, methotrexate):</em></p><p>Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.</p><p><em>Salicylates:</em></p><p>In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the salicylates on the central nervous system.</p><p><em>Methyldopa:</em></p><p>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</p><p><em>Cyclosporine:</em></p><p>Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-type complications.</p><p><em>Tetracyclines:</em></p><p>Concomitant administration of tetracyclines and thiazides increases the risk of tetracycline-induced increase in urea. This interaction is probably not applicable to doxycycline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>The use of <strong>Trioltan<sup>&reg; </sup></strong>is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4). Given the effects of the individual components in this combination product on pregnancy, the use of <strong>Trioltan<sup>&reg; </sup></strong>is not recommended during the first trimester of pregnancy (see section 4.4).</p><p><em>Olmesartan medoxomil</em></p><p>The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4). The use of angiotensin II receptor antagonists is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments, which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to angiotensin II receptor antagonists therapy during the 2nd and 3rd trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3).</p><p>Should exposure to angiotensin II receptor antagonists have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants, whose mothers have taken angiotensin II receptor antagonists should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><em>Hydrochlorothiazide</em></p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the 2nd and 3rd trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or pre-eclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p><em>Amlodipine</em></p><p>Data on a limited number of exposed pregnancies do not indicate that amlodipine or other calcium receptor antagonists have a harmful effect on the health of the fetus. However, there may be a risk of prolonged delivery.</p><p><strong>Breast-feeding</strong></p><p>Because no information is available regarding the use of <strong>Trioltan<sup>&reg; </sup></strong>during breast-feeding, <strong>Trioltan<sup>&reg; </sup></strong>is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.</p><p>Olmesartan is excreted into the milk of lactating rats. However, it is not known whether olmesartan passes into human milk. It is not known whether amlodipine is excreted in breast milk. Similar calcium channel blockers of the dihydropyridine type are excreted in breast milk.</p><p>Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production. The use of <strong>Trioltan<sup>&reg; </sup></strong>during breast-feeding is not recommended. If <strong>Trioltan<sup>&reg; </sup></strong>is used during breast-feeding, doses should be kept as low as possible.</p><p><strong>Fertility</strong></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers.</p><p>Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>However, it should be borne in mind that dizziness, headache, nausea or fatigue may occasionally occur in patients taking antihypertensive therapy and that these symptoms may impair the ability to react. Caution is recommended especially at the start of treatment.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of olmesartan medoxomil/amlodipine/hydrochlorothiazide was investigated in clinical trials in 7826 patients receiving olmesartan medoxomil in combination with amlodipine and hydrochlorothiazide.</p><p>Adverse reactions from clinical trials, post-authorization safety studies and spontaneous reporting are summarized in table 1 for olmesartan medoxomil/amlodipine/hydrochlorothiazide as well as for the individual components olmesartan medoxomil, amlodipine and hydrochlorothiazide based on the known safety profile of the single components.</p><p>The most commonly reported adverse reactions during treatment with olmesartan medoxomil/amlodipine/hydrochlorothiazide are peripheral oedema, headache and dizziness.</p><p>The following terminologies have been used in order to classify the occurrence of undesirable effects:</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p><strong>Table 1: Overview of adverse reactions with olmesartan medoxomil/ amlodipine/ hydrochlorothiazide and the single components</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA</strong></p><p><strong>System Organ Class</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>olmesartan medoxomil/amlodipine/hydrochlorothiazide</strong></p></td><td style="vertical-align:top"><p><strong>Olmesartan</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipin</strong></p></td><td style="vertical-align:top"><p><strong>HCTZ</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Sialadenitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Leucopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow depression</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia/Agranulocytosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Drug hypersensitivity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Glycosuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatriaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercolesterolaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemic alkalosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hyperamylasaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Apathy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Irritability</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Restlessness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Mood changes (including anxiety)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Sleep disorders (including insomnia)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Presyncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Convulsions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Loss of appetite</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Visual disturbance (including diplopia, blurred vision)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Lacrimation decreased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Worsening of myopia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Xanthopsia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Acute myopia, acute angle-closure glaucoma (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon (incl. aggravation of angina pectoris)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis (including necrotising angiitis)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Embolism</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Acute interstitial pneumonia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="16" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Altered bowel habits (including diarrhea and constipation)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Meteorism</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastric irritation</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Paralytic ileus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Sprue-like enteropathy (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestatic icterus)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Acute cholecystitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="19" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous lupus erythematodes-like reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Exanthema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Exfoliative dermatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hyperhydrosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Quincke oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reactivation of cutaneous lupus erythematodes</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Skin discoloration</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Joint swelling</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Ankle swelling</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Paresis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Increased urinary frequency</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Micturition disorder</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nocturia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="11" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="11" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gamma glytamyl transferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatic enzymes increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very rare (mostly consistent with cholestatis)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Weight decrease</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers. Single cases of extrapyramidal syndrome have been reported in patients treated with amlodipine</p><p>Further adverse reactions reported in clinical trials or from post marketing experience with a&nbsp;<u>fixed-dose combination of olmesartan medoxomil and amlodipine</u>&nbsp;and not already reported for olmesartan medoxomil/amlodipine/hydrochlorothiazide, olmesartan medoxomil monotherapy or amlodipine monotherapy or reported in a higher frequency for the dual combination (Table 2):</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 2: Combination of olmesartan medoxomil and amlodipine</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Drug hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Upper abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Libido decreased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pitting oedema</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lethargy</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pain in extremity</p></td></tr></tbody></table><p>Further adverse reactions reported in clinical trials or from post marketing experience with a&nbsp;<u>fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide</u>&nbsp;and not already reported for olmesartan medoxomil/amlodipine/hydrochlorothiazide, olmesartan medoxomil monotherapy or hydrochlorothiazide monotherapy or reported in a higher frequency for the dual combination (Table 3):</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 3: Combination of olmesartan medoxomil and hydrochlorothiazide</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Disturbances in consciousness (such as loss of consciousness)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eczema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculosceletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Minor decreases in mean haemoglobin and haematocrit values</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms:</em></p><p>The maximum dose of olmesartan medoxomil/amlodipine/hydrochlorothiazide is 40/10/25 mg once daily. There is no information on overdosage with olmesartan medoxomil/amlodipine/hydrochlorothiazide in humans. The most likely effect of <strong>Trioltan<sup>&reg;</sup></strong> overdosage is hypotension.</p><p>The most likely effects of olmesartan medoxomil overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.</p><p>Amlodipine overdosage can be expected to lead to excessive peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Marked and potentially prolonged systemic hypotension, up to and including shock with fatal outcome, has been reported.</p><p>Overdosage with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and dehydration resulting from excessive diuresis.</p><p>The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.</p><p><em>Treatment:</em></p><p>In the event of overdosage with <strong>Trioltan<sup>&reg;</sup></strong>, treatment should be symptomatic and supportive. Management depends upon the time since ingestion and the severity of the symptoms.</p><p>If intake is recent, gastric lavage may be considered. In healthy subjects, the administration of activated charcoal immediately or up to 2 hours after ingestion of amlodipine has been shown to reduce substantially the absorption of amlodipine.</p><p>Clinically significant hypotension due to an overdose of olmesartan medoxomil/amlodipine/hydrochlorothiazide requires active support of the cardiovascular system, including close monitoring of heart and lung function, elevation of the extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit. The dialysability of olmesartan or hydrochlorothiazide is unknown.</p><p>The degree to which olmesartan and hydrochlorothiazide are removed by haemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists, calcium channel blockers and diuretics.</p><p>ATC code: C09DX03.</p><p><strong>Trioltan<sup>&reg; </sup></strong>is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, a calcium channel blocker, amlodipine besilate and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than each component alone.</p><p><u>Olmesartan medoxomil</u>&nbsp;is an orally active, selective angiotensin II receptor (type AT<sub>1</sub>) antagonist. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension. The effects of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by blocking its binding to the AT<sub>1</sub>&nbsp;receptor in tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is independent of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT<sub>1</sub>) receptors by olmesartan results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.</p><p>In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.</p><p>Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment.</p><p>The effect of olmesartan medoxomil on mortality and morbidity is not yet known.</p><p>The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in 4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular risk factor, investigated whether treatment with olmesartan could delay the onset of microalbuminuria. During the median follow-up duration of 3.2 years, patients received either olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or ARBs.</p><p>For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.</p><p>For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients (0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26 patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal cardiovascular events.</p><p>The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577 randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other antihypertensive agents including ACE inhibitors.</p><p>The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129 patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53 placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular death in 10 (3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall mortality 19 (6.7%) versus 20 (7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively.</p><p>The&nbsp;<u>amlodipine</u>&nbsp;component of <strong>Trioltan<sup>&reg; </sup></strong>is a calcium channel blocker that inhibits the transmembrane influx of calcium ions through the potential-dependent L-type channels into the heart and smooth muscle. Experimental data indicate that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. Amlodipine is relatively vessel-selective, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. The antihypertensive effect of amlodipine derives from a direct relaxant effect on arterial smooth muscle, which leads to a lowering of peripheral resistance and hence of blood pressure.</p><p>In hypertensive patients, amlodipine causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.</p><p>Following administration of therapeutic doses to patients with hypertension, amlodipine produces an effective reduction in blood pressure in the supine, sitting and standing positions. Chronic use of amlodipine is not associated with significant changes in heart rate or plasma catecholamine levels. In hypertensive patients with normal renal function, therapeutic doses of amlodipine reduce renal vascular resistance and increase glomerular filtration rate and effective renal plasma flow, without changing filtration fraction or proteinuria.</p><p>In haemodynamic studies in patients with heart failure and in clinical studies based on exercise tests in patients with NYHA class II-IV heart failure, amlodipine was found not to cause any clinical deterioration, as measured by exercise tolerance, left ventricular ejection fraction and clinical signs and symptoms.</p><p>A placebo-controlled study (PRAISE) designed to evaluate patients with NYHA class III-IV heart failure receiving digitalis, diuretics and ACE inhibitors, has shown that amlodipine did not lead to an increase in the risk of mortality and morbidity in patients with heart failure.</p><p>In a follow-up, long-term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total or cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.</p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.&rdquo;</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.</p><p><u>Hydrochlorothiazide</u>&nbsp;is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics. With hydrochlorothiazide, onset of diuresis occurs at about 2 hours and peak effect occurs at about 4 hours post-dose, whilst the action persists for approximately 6-12 hours.</p><p>Epidemiological studies have shown that long-term treatment with hydrochlorothiazide monotherapy reduces the risk of cardiovascular mortality and morbidity.</p><p><strong><u>Results of Clinical Studies</u></strong></p><p>In a 12-week, double-blind, randomised, parallel-group study in 2492 patients (67% Caucasian patients), treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide 40/10/25 mg resulted in significantly greater reductions in diastolic and systolic blood pressures than treatment with either of the corresponding dual combinations, olmesartan medoxomil 40 mg plus amlodipine 10 mg, olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg and amlodipine 10 mg plus hydrochlorothiazide 25 mg, respectively.</p><p>The additional blood pressure lowering effect from olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg compared to the analogous dual combinations was between -3.8 and -6.7 mmHg for seated diastolic and between -7.1 and -9.6 mmHg for seated systolic blood pressure and occurred within the first 2 weeks.</p><p>The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non-diabetic patients and &lt; 130/80 mmHg for diabetic patients) at week 12 ranged from 34.9% to 46.6% for the dual combination treatment groups compared to 64.3% for olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg.</p><p>In a second double-blind, randomised, parallel-group study in 2690 patients (99.9% Caucasian patients), treatment with olmesartan medoxomil/amlodipine/hydrochlorothiazide (20/5/12.5 mg, 40/5/12.5 mg, 40/5/25 mg, 40/10/12.5 mg, 40/10/25 mg) resulted in significantly greater reductions in diastolic and systolic blood pressure compared to the corresponding dual combinations, olmesartan medoxomil 20 mg plus amlodipine 5 mg, olmesartan medoxomil 40 mg plus 5 mg amlodipine and olmesartan medoxomil 40 mg plus 10 mg amlodipine, respectively, after 10 weeks of treatment.</p><p>The additional blood pressure lowering effect from olmesartan medoxomil/amlodipine/hydrochlorothiazide compared to the corresponding dual combinations was between -1.3 and -1.9 mmHg for seated diastolic and between -2.7 and -4.9 mmHg for seated systolic blood pressure.</p><p>The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non-diabetic patients and &lt; 130/80 mmHg for diabetic patients) at week 10 ranged from 42.7% to 49.6% for the dual combination treatment groups compared to 52.4% to 58.8% for olmesartan medoxomil/amlodipine/hydrochlorothiazide.</p><p>In a randomised, double-blind, add-on study in 808 patients (99.9 % Caucasian patients) not adequately controlled after 8-weeks therapy with olmesartan medoxomil 40 mg plus amlodipine 10 mg dual combination treatment with olmesartan medoxomil/amlodipine/hydrochlorothiazide resulted in numerically additional seated blood pressure reduction of -1.8/-1.0 mmHg when treated with olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg and a statistically significant additional seated blood pressure reduction of -3.6/-2.8 mmHg when treated with olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg compared to the olmesartan medoxomil 40 mg plus amlodipine 10 mg dual combination.</p><p>Treatment with olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg triple-combination therapy resulted in a statistically significantly greater percentage of subjects reaching their blood pressure goal compared to olmesartan medoxomil 40 mg plus amlodipine 10 mg dual combination therapy (41.3% vs. 24.2%); while the treatment with olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg triple-combination therapy resulted in a numerically greater percentage of subjects reaching their blood pressure goal compared to olmesartan medoxomil 40 mg plus amlodipine 10 mg dual-combination therapy (29.5% vs. 24.2%) in subjects not adequately controlled on dual-combination therapy.</p><p>The antihypertensive effect of olmesartan medoxomil/amlodipine/hydrochlorothiazide was similar irrespective of age and gender, and was similar in patients with and without diabetes.</p><p><strong>Other information:</strong></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of olmesartan medoxomil, amlodipine and hydrochlorothiazide had no clinically-relevant effects on the pharmacokinetics of either component in healthy subjects.</p><p>Following oral administration of olmesartan medoxomil/amlodipine/hydrochlorothiazide in normal healthy adults, peak plasma concentrations of olmesartan, amlodipine and hydrochlorothiazide are reached in about 1.5 to 3 hours, 6 to 8 hours, and 1.5 to 2 hours, respectively. The rate and extent of absorption of olmesartan medoxomil, amlodipine and hydrochlorothiazide from olmesartan medoxomil/amlodipine/hydrochlorothiazide are the same as when administered as a dual-fixed combination of olmesartan medoxomil and amlodipine together with a hydrochlorothiazide single-component tablet or when administered as a dual-fixed combination of olmesartan medoxomil and hydrochlorothiazide together with an amlodipine single-component tablet with the same dosages. Food does not affect the bioavailability of olmesartan medoxomil/amlodipine/hydrochlorothiazide.</p><p><u>Olmesartan medoxomil:</u></p><p><em>Absorption and distribution:</em></p><p>Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.</p><p>The mean peak plasma concentration (C<sub>max</sub>) of olmesartan is reached within about 2 hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80 mg.</p><p>Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.</p><p>No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.</p><p>Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound co-administered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).</p><p><em>Biotransformation and elimination:</em></p><p>Total plasma clearance of olmesartan was typically 1.3 L/h (CV 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of&nbsp;<sup>14</sup>C-labelled olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated (see section 4.3).</p><p>The terminal elimination half-life of olmesartan varied between 10 and 15 hours after multiple oral dosing. Steady state was reached after 2-5 days of dosing and no further accumulation was evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 &ndash; 0.7 L/h and was independent of dose.</p><p><em>Drug interactions:</em></p><p>Bile acid sequestering agent colesevelam:</p><p>Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in C<sub>max</sub>&nbsp;and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in C<sub>max</sub>&nbsp;and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride. Elimination half-life of olmesartan was reduced by 50 &ndash; 52% irrespectively of whether administered concomitantly or 4 hours prior to colesevelam hydrochloride (see section 4.5).</p><p><u>Amlodipine</u>:</p><p><em>Absorption and distribution:</em></p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg. In vitro studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The absorption of amlodipine is unaffected by the concomitant intake of food.</p><p><em>Biotransformation and elimination:</em></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing.</p><p>Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><u>Hydrochlorothiazide:</u></p><p><em>Absorption and distribution:</em></p><p>Following oral administration of olmesartan medoxomil and hydrochlorothiazide in combination, the median time to peak concentrations of hydrochlorothiazide was 1.5 to 2 hours after dosing. Hydrochlorothiazide is 68% protein bound in the plasma and its apparent volume of distribution is 0.83 &ndash; 1.14 L/kg.</p><p><em>Biotransformation and elimination:</em></p><p>Hydrochlorothiazide is not metabolised in man and is excreted almost entirely as unchanged active substance in urine. About 60% of the oral dose is eliminated as unchanged active substance within 48 hours. Renal clearance is about 250 &ndash; 300 mL/min. The terminal elimination half-life of hydrochlorothiazide is 10 &ndash; 15 hours.</p><p><strong>Pharmacokinetics in special populations</strong></p><p><em>Paediatric Population:</em></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with olmesartan medoxomil/amlodipine/hydrochlorothiazide in all subsets of the paediatric population in essential hypertension.</p><p><em>Elderly (age 65 years or over)</em>:</p><p>In hypertensive patients, the olmesartan AUC at steady state was increased by ca 35% in elderly people (65-75 years old) and by ca 44% in very elderly people (&ge; 75 years old) compared with the younger age group (see section 4.2).</p><p>This may be at least in part related to a mean decrease in renal function in this group of patients. The recommended dosage regimen for elderly people is, however, the same, although caution should be exercised when increasing the dosage.</p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly people. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group in this study (see section 4.4).</p><p>Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly people compared to young healthy volunteers.</p><p><em>Renal impairment:</em></p><p>In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2 and 4.4). The pharmacokinetics of olmesartan medoxomil in patients undergoing haemodialysis has not been studied.</p><p>Amlodipine is extensively metabolised to inactive metabolites. Ten percent of the substance is excreted unchanged in the urine. Changes in amlodipine plasma concentration are not correlated with the degree of renal impairment. In these patients, amlodipine may be administered at the normal dosage. Amlodipine is not dialysable.</p><p>The half-life of hydrochlorothiazide is prolonged in patients with impaired renal function.</p><p><em>Hepatic impairment:</em></p><p>After single oral administration, olmesartan AUC values are 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment is 0.26%, 0.34% and 0.41%, respectively.</p><p>Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC is again about 65% higher than in matched healthy controls. Olmesartan mean C<sub>max</sub>&nbsp;values are similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see sections 4.2 and 4.4).</p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. The clearance of amlodipine is decreased and the half-life is prolonged in patients with impaired hepatic function, resulting in an increase in AUC of about 40% &ndash; 60% (see sections 4.2 and 4.4).</p><p>Hepatic impairment does not significantly influence the pharmacokinetics of hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olmesartan medoxomil/ Amlodipine /Hydrochlorothiazide combination</p><p>Repeated dose toxicity study in rats demonstrated that the combined administration of olmesartan medoxomil, amlodipine and hydrochlorothiazide neither augmented any of the previously reported and existing toxicities of the individual agents, nor induced any new toxicity, and no toxicologically synergistic effects were observed.</p><p>No additional mutagenicity, carcinogenicity, and reproductive toxicity studies for olmesartan medoxomil/amlodipine/hydrochlorothiazide have been conducted based on the well-understood safety profile of the individual active ingredients.</p><p><strong>Olmesartan medoxomil</strong></p><p>In chronic toxicity studies in rats and dogs, olmesartan medoxomil showed similar effects to other AT<sub>1</sub>&nbsp;receptor antagonists and ACE inhibitors: raised blood urea (BUN) and creatinine; reduction in heart weight; reduction of red cell parameters (erythrocytes, haemoglobin, haematocrit); histological indications of renal damage (regenerative lesions of the renal epithelium, thickening of the basal membrane, dilatation of the tubules). These adverse effects caused by the pharmacological action of olmesartan medoxomil have also occurred in preclinical trials on other AT<sub>1</sub>&nbsp;receptor antagonists and ACE inhibitors and can be reduced by simultaneous oral administration of sodium chloride.</p><p>Like other AT<sub>1</sub>&nbsp;receptor antagonists olmesartan medoxomil was found to increase the incidence of chromosome breaks in cell cultures in vitro, but not in vivo. The overall data of a comprehensive genotoxicity testing programme suggest that olmesartan is very unlikely to exert genotoxic effects under conditions of clinical use.</p><p>Olmesartan medoxomil was not carcinogenic in rats or transgenic mice.</p><p>In reproductive studies in rats, olmesartan medoxomil did not affect fertility and there was no evidence of a teratogenic effect. In common with other angiotensin II antagonists, survival of offspring was reduced and pelvic dilatation of the kidney was seen after exposure of the dams in late pregnancy and lactation. In rabbits there was no indication of a fetotoxic effect.</p><p>Amlodipine</p><p>Reproductive toxicology</p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p>Impairment of fertility</p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>Carcinogenesis, mutagenesis</p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>*Based on patient weight of 50 kg</p><p>Hydrochlorothiazide</p><p>Studies with hydrochlorothiazide have shown equivocal evidence for a genotoxic or carcinogenic effect in some experimental models. However, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry II Yellow, Opadry II Pink, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Trioltan&reg; 40/5/12.5 mg tables </strong>are Light yellow, round, biconvex, film-coated tablets debossed with &lsquo;T22&rsquo; on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.<br /><strong>Pack size:</strong> 28 Film Coated tablets.<br /><strong>Trioltan&reg; 40/10/12.5 mg tables</strong> are Grayish red, round, biconvex, film-coated tablets debossed with &lsquo;T24&rsquo; on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.<br /><strong>Pack size:</strong> 28 Film Coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
1st Industrial city, Phase 5, Jeddah –KSA.
Tel: 00966920003288
Mobile: 00966555786968
P.O .Box: 4072 - Jeddah 22429
E-mail:  info@medcitypharma.com
Manufacturer:               
Macleods Pharmaceuticals Limited – India. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>